<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31015341</article-id>
<article-id pub-id-type="pmc">6595945</article-id>
<article-id pub-id-type="publisher-id">3014-18</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.3014-18.2019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group>
<subject>Cellular/Molecular</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Antagonizing Increased <italic>miR-135a</italic> Levels at the Chronic Stage of Experimental TLE Reduces Spontaneous Recurrent Seizures</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-0751-9772</contrib-id>
<name>
<surname>Vangoor</surname>
<given-names>Vamshidhar R.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reschke</surname>
<given-names>Cristina R.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Senthilkumar</surname>
<given-names>Ketharini</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-3800-7999</contrib-id>
<name>
<surname>van de Haar</surname>
<given-names>Lieke L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Wit</surname>
<given-names>Marina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giuliani</surname>
<given-names>Giuliano</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Broekhoven</surname>
<given-names>Mark H.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morris</surname>
<given-names>Gareth</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-9137-0637</contrib-id>
<name>
<surname>Engel</surname>
<given-names>Tobias</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brennan</surname>
<given-names>Gary P.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5983-8682</contrib-id>
<name>
<surname>Conroy</surname>
<given-names>Ronan M.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Rijen</surname>
<given-names>Peter C.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gosselaar</surname>
<given-names>Peter H.</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-1541-5148</contrib-id>
<name>
<surname>Schorge</surname>
<given-names>Stephanie</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-9014-4301</contrib-id>
<name>
<surname>Schaapveld</surname>
<given-names>Roel Q.J.</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Henshall</surname>
<given-names>David C.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>De Graan</surname>
<given-names>Pierre N.E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-1631-6440</contrib-id>
<name>
<surname>Pasterkamp</surname>
<given-names>R. Jeroen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, 3584 CG Utrecht, The Netherlands, </aff>
<aff id="aff2"><sup>2</sup>Department of Physiology and Medical Physics, </aff>
<aff id="aff3"><sup>3</sup>FutureNeuro Research Centre, Royal College of Surgeons in Ireland, Dublin D02, Ireland, </aff>
<aff id="aff4"><sup>4</sup>Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, London WC1N 3BG, United Kingdom, </aff>
<aff id="aff5"><sup>5</sup>Department of Epidemiology and Public Health Medicine, Royal College of Surgeons in Ireland, Dublin D02 YN77, Ireland, </aff>
<aff id="aff6"><sup>6</sup>Department of Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, 3584 CG, Utrecht, The Netherlands, and </aff>
<aff id="aff7"><sup>7</sup>InteRNA Technologies 3584 CM Utrecht, The Netherlands</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to R. Jeroen Pasterkamp at <email>r.j.pasterkamp@umcutrecht.nl</email>.</corresp>
<fn fn-type="con">
<p>Author contributions: V.R.V., C.R.R., K.S., L.L.v.d.H., G.G., G.M., D.C.H., P.N.E.D.G., and R.J.P. designed research; V.R.V., C.R.R., K.S., L.L.v.d.H., M.d.W., G.G., M.H.B., G.M., T.E., and G.P.B. performed research; V.R.V., C.R.R., K.S., L.L.v.d.H., M.d.W., G.G., M.H.B., G.M., G.P.B., R.M.C., and R.J.P. analyzed data; V.R.V. and R.J.P. wrote the paper; P.C.v.R., P.H.G., S.S., and R.Q.J.S. contributed unpublished reagents/analytic tools.</p>
</fn>
<fn fn-type="equal" id="FN1">
<p>*C.R.R. and K.S. contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>26</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>26</day>
<month>12</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>39</volume>
<issue>26</issue>
<fpage>5064</fpage>
<lpage>5079</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>31</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2019 the authors</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="zns02619005064.pdf"></self-uri>
<abstract>
<p>Mesial temporal lobe epilepsy (mTLE) is a chronic neurological disease characterized by recurrent seizures. The antiepileptic drugs currently available to treat mTLE are ineffective in one-third of patients and lack disease-modifying effects. miRNAs, a class of small noncoding RNAs which control gene expression at the post-transcriptional level, play a key role in the pathogenesis of mTLE and other epilepsies. Although manipulation of miRNAs at acute stages has been reported to reduce subsequent spontaneous seizures, it is uncertain whether targeting miRNAs at chronic stages of mTLE can also reduce seizures. Furthermore, the functional role and downstream targets of most epilepsy-associated miRNAs remain poorly understood. Here, we show that <italic>miR-135a</italic> is selectively upregulated within neurons in epileptic brain and report that targeting <italic>miR-135a in vivo</italic> using antagomirs after onset of spontaneous recurrent seizures can reduce seizure activity at the chronic stage of experimental mTLE in male mice. Further, by using an unbiased approach combining immunoprecipitation and RNA sequencing, we identify several novel neuronal targets of <italic>miR-135a</italic>, including <italic>Mef2a</italic>. Mef2 proteins are key regulators of excitatory synapse density. Mef2a and <italic>miR-135a</italic> show reciprocal expression regulation in human (of both sexes) and experimental TLE, and <italic>miR-135a</italic> regulates dendritic spine number and type through Mef2. Together, our data show that <italic>miR-135a</italic> is target for reducing seizure activity in chronic epilepsy, and that deregulation of <italic>miR-135a</italic> in epilepsy may alter <italic>Mef2a</italic> expression and thereby affect synaptic function and plasticity.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> miRNAs are post-transcriptional regulators of gene expression with roles in the pathogenesis of epilepsy. However, the precise mechanism of action and therapeutic potential of most epilepsy-associated miRNAs remain poorly understood. Our study reveals dramatic upregulation of the key neuronal miRNA <italic>miR-135a</italic> in both experimental and human mesial temporal lobe epilepsy. Silencing <italic>miR-135a</italic> in experimental temporal lobe epilepsy reduces seizure activity at the spontaneous recurrent seizure stage. These data support the exciting possibility that miRNAs can be targeted to combat seizures after spontaneous seizure activity has been established. Further, by using unbiased approaches novel neuronal targets of <italic>miR-135a</italic>, including members of the Mef2 protein family, are identified that begin to explain how deregulation of <italic>miR-135a</italic> may contribute to epilepsy.</p>
</abstract>
<kwd-group>
<kwd>antagomirs</kwd>
<kwd>epilepsy</kwd>
<kwd>Mef2</kwd>
<kwd>mesial temporal lobe epilepsy</kwd>
<kwd>miRNA</kwd>
<kwd>RNA sequencing</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>